ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Immune mechanisms in fibrotic pulmonary sarcoidosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Isolated cardiac sarcoidosis: A systematic review.The Journal of international medical research · 2025Pooled it
- The theory of the inflammatory ecosystem.Science China. Life sciences · 2026Review
- Concurrency of systemic sclerosis and sarcoidosis: a case-based review.Clinical rheumatology · 2025Review
- Pathological diversity of pulmonary sarcoidosis.Frontiers in medicine · 2025Review
- Imbalance of B-Cell Subpopulations in the Microenvironment of Sarcoidosis or Lung Cancer.Cells · 2024Article
- Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis.The Journal of clinical investigation · 2024Review
- Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis.Journal of clinical medicine · 2023Review
- Emerging Therapeutic Options for Refractory Pulmonary Sarcoidosis: The Evidence and Proposed Mechanisms of Action.Journal of clinical medicine · 2023Review
- Circulating Regulatory T Cell Subsets in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2023Article
- Immune-mediated lung diseases: A narrative review.Frontiers in medicine · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area. Consequently, there has been little change in the clinical management of fibrotic sarcoidosis over the decades and an unfocused search for new therapeutics. In this review, we provide a comprehensive examination of the relevant immune findings in fibrotic and/or progressive pulmonary sarcoidosis and propose a unifying mechanism for the pathobiology of fibrosis in sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.